Robust RAPIDe-3 Deucrictibant Data Might Change The Case For Investing In Pharvaris (PHVS)

• Earlier in June 2026, Pharvaris reported Phase 3 RAPIDe-3 data and long-term extension results at EAACI, highlighting rapid symptom relief, sustained hereditary angioedema control, and supportive cardiovascular safety findings for oral deucrictibant in both on-demand and prophylactic use.
• An especially interesting insight was that nearly half of interviewed RAPIDe-3 participants described an improved day-to-day treatment experience with oral deucrictibant versus prior injectable therapies, alongside broad health-related quality-of-life gains.
• Against this backdrop, we’ll explore how the robust Phase 3 RAPIDe-3 efficacy data for oral deucrictibant may influence Pharvaris’ investment narrative.

The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

What Is Pharvaris' Investment Narrative?

To own Pharvaris, you need to believe that oral deucrictibant can become a standard hereditary angioedema therapy across both on-demand and prophylactic settings, and that the company can ultimately translate that into sustainable commercial revenue. The latest EAACI data sharpen that thesis rather than transform it: RAPIDe-3 reinforces rapid attack control, CHAPTER-1 extension results support long-term use and combination regimens, and the integrated cardiovascular analysis helps address a key safety question ahead of regulatory filings. These readouts likely strengthen the near-term catalyst path around global marketing applications for the immediate-release capsule and the CHAPTER-3 prophylaxis topline expected later in 2026, without obviously altering timing. The bigger picture risk remains execution: Pharvaris is loss-making, recently raised equity, and is still several critical regulatory and launch steps away from proving its commercial model.

Yet there is one particular execution risk here that investors should not overlook.

Pharvaris' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

The Simply Wall St Community’s single fair value estimate centers on €45.99, but community views can still diverge meaningfully as new data land. Against that, the recent clinical wins sharpen the focus on regulatory decisions as the next key test for Pharvaris, which could have broad implications for how the market values the company’s cash-burning R&D engine.

Explore another fair value estimate on Pharvaris - why the stock might be worth as much as 38% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Pharvaris research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Pharvaris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pharvaris' overall financial health at a glance.

Looking For Alternative Opportunities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Find 43 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com